Generate Biomedicines Is Maintained at Overweight by Morgan Stanley

Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley

Morgan Stanley Lifts Price Target on Generate Biomedicines to $22 From $20, Keeps Overweight Rating

Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)

Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co.

Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M

Earnings Flash (GENB) Generate Biomedicines Posts Q1 Net Loss $61.4M, vs. FactSet Est of $61.2M Loss

Generate Biomedicines : Believes Existing Cash, Cash Equivalents, Marketable Securities Will Be Sufficient to Fund Operations Into First Half of 2028

Generate Biomedicines Inc - Q1 Revenue $7.2 Mln

Generate Biomedicines Inc: Expects to Require Additional Capital to Support Long-Term Operations

Press Release: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Q1 FY26 net loss widens to $61.7 million; revenue falls to $7.2 million

Generate Biomedicines Initiated at Buy by HC Wainwright & Co.

Generate Biomedicines initiated with a Buy at H.C. Wainwright

Buy Rating on Generate Biomedicines Driven by Differentiated Pipeline, GB-0895 Asthma Opportunity, and AI-Enabled Protein Platform

Generate Biomedicines publishes corporate presentation on programmable biology drug design platform

BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug

Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Generate Biomedicines Initiated at Overweight by Piper Sandler